Ciliary neurotrophic factor not checked

Neurotech Pharmaceuticals · NT-501

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
2 active
10 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“NT-501 is surgically implanted into the vitreous cavity to continuously release recombinant human ciliary neurotrophic factor (CNTF).”In the company’s words, NCT06971939 on ClinicalTrials.gov
Tested for
Macular Telangiectasia Type 2 (MacTel), Macular Telangiectasia Type 2
Main trialPhase 4
“The purpose of this global, multicenter, open-label, Phase 4 clinical extension study is to evaluate the long-term safety and efficacy of revakinagene taroretcel-lwey (Encelto™; hereinafter referred to as NT-501), in participants with macular telangiectasia type 2 (MacTel) who previously received the intraocular implant in a Phase 1, Phase 2, or Phase 3 clinical study and have retained at least 1 NT-501 at study entry. In addition, this study will evaluate the safety and efficacy of NT501 in participants who previously underwent the sham procedure in a Phase 3 MacTel clinical study and elect…”In the company’s words, NCT06971939 on ClinicalTrials.gov
Other names
NT-501 · CNTF · Encapsulated Cell Therapy · ECT · CNTF implant · ENCELTO · M-CHFM · CHFM

Other drugs for Macular Telangiectasia Type 2

All 98 drugs for Macular Telangiectasia Type 2

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials10

TrialPhaseCompletesWhat it tests
Phase 4Recruiting 15 Jan 2032 Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants
Phase 3Recruiting 1 May 2028 A Study to Determine the Safety and Efficacy of NT-501 With M-CHFM
Phase 3Completed 31 Aug 2022 A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A
Phase 3Completed 31 Aug 2022 A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol B
Phase 2Completed 11 May 2009 A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration
Phase 2Completed 26 May 2009 A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa
Phase 2Completed 19 Apr 2010 A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa
Phase 2Completed 1 Jul 2019 Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa
Phase 2Completed 11 May 2021 Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel)
Phase 2Completed 8 Dec 2022 Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Ciliary neurotrophic factor

Following is part of Solo: you see every change to Ciliary neurotrophic factor the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in